- Featured Product
- KD/KO Validated
CoraLite® Plus 647-conjugated ACLY Polyclonal antibody
ACLY Polyclonal Antibody for FC (Intra)
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
FC (Intra)
Conjugate
CoraLite® Plus 647 Fluorescent Dye
Cat no : CL647-15421
Synonyms
Validation Data Gallery
Tested Applications
Positive FC (Intra) detected in | HepG2 cells |
Recommended dilution
Application | Dilution |
---|---|
Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.20 ug per 10^6 cells in a 100 µl suspension |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
CL647-15421 targets ACLY in FC (Intra) applications and shows reactivity with human, mouse, rat samples.
Tested Reactivity | human, mouse, rat |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | ACLY fusion protein Ag7709 |
Full Name | ATP citrate lyase |
Calculated Molecular Weight | 121 kDa |
Observed Molecular Weight | 120 kDa |
GenBank Accession Number | BC006195 |
Gene Symbol | ACLY |
Gene ID (NCBI) | 47 |
Conjugate | CoraLite® Plus 647 Fluorescent Dye |
Excitation/Emission Maxima Wavelengths | 654 nm / 674 nm |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
ACLY(ATP-citrate synthase) is also named as ACL. It is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA. ACLY serves as not only a target in oxygenated cells for suppression of lipid synthesis and histone acetylation, but also as a susceptible target in hypoxic cells to restore inhibition of glycolysis. In nonsmall cell lung carcinoma and hepatocellular carcinoma, ACLY is overexpressed compared with normal parenchyma suggesting that ACLY may represent a common target among highly malignant tumors(PMID:19795461). This protein has 2 isoforms produced by alternative splicing.